Navigation Links
Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
Date:5/14/2008

NANJING, China, May 14 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced that the Company's senior management will present at the following investor conferences:

* Brean Murray Carret & Co. All Cap China Conference at the

Waldorf-Astoria in New York on Monday, May 19, 2008 at 2:00 p.m. ET

* Oppenheimer & Co. 2nd Annual China Dragon Call Conference at

Oppenheimer's 300 Madison Avenue offices in New York on Tuesday,

May 20, 2008 at 3:10 p.m. ET

* Citigroup Global Healthcare Conference at the Hilton Hotel in New York

on Wednesday, May 21, 2008 at 4:30 p.m. ET

The presentation slides will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer me
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , 15 septembre 2014 La deuxième ... (IPAW) (semaine internationale sur la sensibilisation au ... Initiative conjointe de la Plasma Protein Therapeutics ... membres , l,IPAW vise à : ... de la collecte du plasma-aphérèse , Reconnaître ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
(Date:9/12/2014)... a magnet using an electric field (magnetoelectric memory ... the next-generation technology for information processing and storage. ... effect, due to the coexistence of electric and ... of spontaneous electric and magnetic polarizations is rare ... of the MEM effect. This article briefly reviews ...
(Date:9/12/2014)... September 12, 2014 Today, “The University” ... Indiegogo. , The film, directed by former Charlie ... Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and others. ... there’s only one university in the world devoted to ... the lives of a billion people: Singularity University. Matt ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... SAN DIEGO , INDIANAPOLIS , and WALTHAM, Mass. , June ... Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable ... diabetes medications. , , , ...
... Inc. (Nasdaq: ISIS ) announced today that it will conduct the fourth ... Isis, development pipeline.  The last call of the series will focus on Isis, ... at 12:00 p.m. ET .  This call will be archived for a ... , , ...
... , June 15, 2010 Pieris AG,announced today the initiation ... PRS-050, an anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of the ... in, Germany , the trial is underway and patients from the first ... , ...
Cached Biology Technology:DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 2DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 4DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 5DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 6DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 7DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 8DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 9Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 2Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 3Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2
(Date:9/15/2014)... 2014 Schizophrenia is generally considered to be a ... factors, both genetic and environmental, with other neurodevelopmental disorders ... path for brain development is determined by the combined ... wide range of environmental factors. , However, longitudinal brain ... required in order to map the disturbances in brain ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... available in German . ... the fossil energy carrier natural gas offers a variety ... Nevertheless, a consequent market penetration is still pending because ... Scientists of the Helmholtz Centre for Environ-mental Research (UFZ) ... Members of the IEA Task 37 (Energy from Biogas) ...
Breaking Biology News(10 mins):Brain Development in Schizophrenia Strays from the Normal Path 2The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3
... multicenter clinical trial led by a researcher at the ... will evaluate a new approach to treat triple-negative breast ... common among African-Americans and young women. The study will ... reprogram tumor cells to express a protein called an ...
... Institution (WHOI) will lead the first international, multidisciplinary assessment ... the Pacific Ocean off the Fukushima nuclear power planta ... Foundation. "This project will address fundamental ... to the ocean, and in the process enhance international ...
... can sometimes be desirable such as in the taste ... rejection that can interfere with food selection, nutrition and therapeutic ... the Monell Center and Integral Molecular describe the discovery of ... subset of bitter taste receptors. "Bitter taste is ...
Cached Biology News:New clinical trial to test novel approach to treat triple-negative breast cancer 2New clinical trial to test novel approach to treat triple-negative breast cancer 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 4Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 5New bitter blocker discovered 2
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: